Correlations between cerebellar and brain volumes, cognitive impairments, ApoE levels, and APOE genotypes in patients with AD and MCI

Current Alzheimer Research

Volumn 10, Issue 9, 2013, Pages 964-972

  Łojkowska, Wanda ^a   Witkowski, Grzegorz ^a   Bednarska Makaruk, Małgorzata ^a   Wehr, Hanna ^a   Sienkiewicz Jarosz, Halina ^a   Graban, Ałła ^a   Bochyńska, Anna ^a   Wiśniewska, Anna ^a   Gugała, Magdalena ^a   Sławińska, Ksenia ^a   Sawicka, Beata ^a   Poniatowska, Renata ^a   Ryglewicz, Danuta ^a  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Alzheimer's disease; APOE genotype; Apolipoprotein E; Brain volume; Cerebellum; Mild cognitive impairment

Indexed keywords

APOLIPOPROTEIN E;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN SIZE; BRAIN STEM; CEREBELLUM; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE COURSE; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEINS E; ATROPHY; BRAIN; CEREBELLUM; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; GENOTYPE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; ORGAN SIZE;

EID: 84888223258     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/15672050113106660161     Document Type: Article

References (56)

1. Daum I, Ackermann H, Schugens MM, Reimold C, Dichgans J, Birbaumer N. The cerebellum and cognitive functions in humans Behav. Neurosci 107: 411-419 (1993).
2. Schmahmann JD, Sherman JC. The cerebellar cognitive affective syndrome. Brain 121: 561-79 (1998).
3. Desmond JE, Fiez JA. Neuroimaging studies of cerebellum: lan-guage, learning and memory. Trends Cogn Sci 2: 355-361 (1998).
4. Ackermann H, Mathiak K, Riecker A. The contribution of the cerebellum to speech production and speech perception: clinical and functional imaging data. Cerebellum 6: 202-213 (2007).
5. Wegiel J, Wisniewski HM, Dziewiatkowski J, Badmajew E, Tar-nawski M, Reisberg B, et al. Cerebellar atrophy in Alzheimer's disease - clinicopathological correlations. Brain Res 818: 41-50 (1999).
6. Braak H, Braak E, Bohl J, Lang W. Alzheimer's disease: Amyloid plaques in the cerebellum. J Neurol Sci 93: 277-287 (1989).
7. Joachim CL, Morris JH, Selkoe DJ. Diffuse plaques occur com-monly in the cerebellum in Alzheimer's disease. Am J Pathol 135: 309-319 (1989).
8. Wang HY, D'Andrea MR, Nagele RG. Cerebellar diffuse amyloid plaques are derived from dendritic Aβ342 accumulations in Purkinje cells. Neurobiol Aging 23: 213-223 (2002).
9. Teipei SJ, Prussner JC, Feltraco F, Born C, Rocha-Unold M, Evans A, et al. Comprehensive dissection of the medial temporal lobe in AD:measurement of hippocampus,amygdala, entorhinal, perirhinal and parahippocampal cortices using MRI. J Neurol 253: 794-800 (2006).
10. Lojkowska W, Sawicka B, Gugala M, Sienkiewicz-Jarosz H, Bo-chynska A, Scinska A, et al. Follow-up study of olfactory deficits, cognitive functions and volume loss of medial temporal lobe structures in patients with Mild Cognitive Impairment. Curr Alzh Res 8: 689-698 (2011).
11. Thomann PA, Schläfer Ch, Seidl U, De Santos V, Essig M, Schröder J. The cerebellum in mild cognitive impairment and Alz heimer's disease - a structural MRI study. J Psychiatr Res 42: 1198-1202 (2008).
12. Baldacara L, Borgio JG, Moraes WA, Lacerda AL, Montano MB, Tufik S, et al. Cerebellar volume in patients with dementia. Rev. Bras. Psiquiatr 33: 122-129 (2011).
13. Bas O, Acer N, Mas N, Karabekir HS, Kusbeci OY, Sahin B. Stereological evaluation of the volume and volume fraction of intracranial structures in magnetic resonance images of patients with Alzheimer's disease. Ann Anat 191: 186-195 (2009).
14. Hayashi N, Sanada S, Suzuki M, Matsuura Y, Kawahara K, Tsujii H, et al. Semiautomatedvolumetry of the cerebrum, cerebellum-brain stem and temporal lobe on brain magnetic resonance images. Radiat Med 26: 104-114 (2008).
15. Kusbeci OY, Bas O, Gocmen-Mas N, Karabekir HS, Yucel A, Ertekin T, et al. Evaluation of cerebellar asymmetry in Alzheimer' s disease: a stereological study. Dement Geriatr Cogn Disord 28: 1-5 (2009).
16. Canu E, McLaren DG, Fitzgerald ME, Bendlin BB, Zoccatelli G, Alessandrini F, et al. Microstructural diffusion changes are independent of macrostructural volume loss in moderate to severe Alzheimer's disease. J Alzheimers Dis 19: 963-976 (2010).
17. Ishii K, Sasaki M, Kitagaki H, Yamaji S, Sakamoto S, Matsuda K. Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease. J Nuclear Med 38: 925-928 (1997).
18. Andersen K, Andersen BB, Pakkenberg B. Stereological quantification of the cerebellum in patients with Alzheimer's disease. NeurobiolAging 33:197 (2012).e11-20.doi:10.1016/j. neurobiolag-ing.2010.06.013. Epub 2010 Aug 21.
19. Sluimer JD, Vrenken H, Blankenstein MA, Fox NC, Scheltens P, Barkhof F, et al. Whole-brain atrophy rate in Alzheimer disease: identifying fast progressors. Neurology 70: 1836-1841(2008).
20. Baum L, Chen L, Ng HK, Pang CP: Apolipopreotein E isoforms in Alzheimer's disease pathology and etiology. Microsc Res Tech 50: 278-281 (2000).
21. Bigler ED, Lowry CM, Anderson CV, Johnson SC, Terry J, Steed M. Dementia, quantitative neuroimaging and Apolipoprotein E genotype. Am J Neuroradiol 21: 1857-1868 (2000).
22. Devanand DP, Pelton GH, Zamora D, Liu X, Tabert MH, Good-kind M, et al. Predictive utility of apolipoprotein E genotype for Alzheimer's disease in outpatients with mild cognitive impairment. Arch Neurol 62: 975-980 (2005).
23. Wehr H, Bednarska-Makaruk M, Graban A, Kunicki PK, Lojkowska W, Rodo M, et al. Apolipoprotein E polymorphism and low density lipoprotein oxidation in patients with dementia. Folia Neuropathol 41: 65-68 (2003).
24. Hamalainen A, Grau-Olivares M, Tervo S, Niskanen E, Pennanen C, Huuskonen J, et al. Apolipoprotein E epsilon 4 allele is associated with increased atrophy in progressive mild cognitive impairment: a voxel- based morphometric study. Neurodegener Dis 5: 186-189 (2008).
25. Ramakers IH, Visser PJ, Aalten P, Bekers O, Sleegers K, van Broeckhoven CL, et al. The association between APOE genotype and memory dysfunction in subjects with mild cognitive impairment is related to age and Alzheimer pathology. Dement Geriatr Cogn Disord 26: 101-108 (2008).
26. Religa D, Styczynska M, Peplonska B, Gabryelewicz T, Pfeffer A, Chodakowska M, et al. Homocysteine, apolipoproteine and meth-ylenetetrahydrofolatereductase in Alzheimer's disease and mild cognitive impairment. Dement Geriatr Cogn Disord 16: 64-70 (2003).
27. Lippa CF, Smith TW, Saunders AM, Hulette C, Pulaski-Salo D, Roses AD. Apolipoprotein E-epsilon 2 and Alzheimer's disease: genotype influences pathologic phenotype. Neurology 48: 515-519 (1997).
28. Pirttilä T, Soininen H, Mehta PD, Heinonen O, Lehtimäki T, Bog-danovic N, et al. Apolipoprotein E genotype and amyloid load in Alzheimer's disease and control brains. Neurobiol Aging 18: 121-127 (1997).
29. Slooter AJ, Roses AD, Apolipoprotein E epsilon 4 and the risc of dementia with stroke. A population based investigation. JAMA 277: 818-821 (1997).
30. Kim J, Basak JB, Holtzman DM. The role of apolipoprotein E in Alzheimer's Dissease. Neuron 63: 287-303 (2009).
31. Donahue JE, Johnson CE: Apolipoprotein E, amyloid-beta and blood-brain barrier permeability in Alzheimer's disease. J Neuro-pathol Exp Neurol 67: 261-270 (2008).
32. Geroldi C, Laakso MP, DeCarli C, Beltramello A, Bianchetti A, Soininen H, et al. Apolipoprotein E genotype and hippocampal asymmetry in Alzheimer's disease: a volumetric MRI study. J Neu-rol Neurosurg Psychiatry 68: 93-96 (2000).
33. Song F, Poljak A, Crawford J, Kochan NA, Wen W, Cameron B, et al. Plasma Apolipoprotein levels are associated with cognitive status and decline in cohort of older individuals. PLOS One 2012, 7, e34078 doi 10.1371/journal pona 0034078.
34. Gupta VB, Laws SM, Villemagne VL, Ames D, Bush Al, Ellis KA, et al., AIBL Research Group. Plasma Apolipoprotein E and Alzheimer's disease risk: the AIBL study of aging. Neurology 76: 1091-1098 (2011).
35. Pirtillä T, Koivisto K, Mehta PD, Reinikainen K, KIms KS, Kilkku O, et al. Longitudinal study of cerebrospinal fluid amyloid proteins and apolipoprotein E in patients with probable Alzheimer's disease. Neurosci Lett 249: 21-24 (1998).
36. Siest G, Bertrand P, Qin B, Herbeth B, Serot JM, Masana L, et al. Apolipoprotein E and serum concentration in Alzheimer's disease in nine European centres: the ApoEurope study. Apo Eurogroup Clin Chem Lab Med 38: 721-730 (2000).
37. Maloney B, Ge YW, Petersen RC, Hardy J, Perez-Tur J, Lahiri DK. Functional characterization of three single -nucleotide polymorphisms present in the human APOE propmoter sequence: Differential effects in neuronal cells and on DNA-protein interactions. Am J Med Genet B Neuropsychiatr Genet 153B: 185-201 (2010).
38. Darreh-Shori T, Forsberg A, Modiri N, Andreasen N, Blennow K, Kamil C, et al. Differential levels of apolipoprotein E and butyryl-cholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo. Neurobiol Aging 32: 2320 (2011).
39. Schiele F, De Bacquer D, Vincent-Viry M, Beisiegel U, Ehnholm C, Evans A, et al. ApolipoproteinE serum concentration and polymorphism in six european countries: the ApoEurope Project. Atherosclerosis 152: 475-488 (2000).
40. Scacchi R, Gambina G, Ruggeri M, Martini MC, Ferrari G, Silves-tri M, et al. Plasma levels of apolipoprotein E and genetic markers in elderly patients with Alzheimer's disease. Neurosci Lett 259: 33-36 (1999).
41. Taddei K, Clamette R, Gandy SE, Martins RN. Increased plasma apolipoprotein E (apoE) levels in Alzheimer's disease. Neurosci Lett 223: 29-32 (1997).
42. Slooter AJ, de Knijff P, Hofman A, Cruts M, Breteler MM, Van Broeckhoven C, et al. Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study. Neurosci Lett 248: 21-24 (1998).
43. Chen K, Reiman EM, Alexander GE, Caselli RI, Gerkin R, Bandy D, et al. Correlations between apolipoprotein E epsilon4 gene dose and whole brain atrophy rates. Am J Psychiatry 164: 916-921(2007).
44. Hoogendam YY, van der Geest JN, van der LIjn F, van der Lugt A, Niessen WJ, Krestin GP, et al. Determinants of cerebellar and cerebral volume in the general elderly population. Neurobiol Aging 33: 2774-2781 (2012).
45. Geroldi C, Laakso MP, DeCarli C, Beltramello A, Bianchetti A, Soininen H, et al. Apolipoprotein E genotype and hippocampal asymmetry in Alzheimer's disease: a volumetric MRI study. J Neurol Neurosurg Psychiatry 68: 93-96 (2000).
46. McKhann G. Drachman D, Fostein M, Katzman R, Price D, Stad-lan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944 (1984).
47. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol 58: 1985-1992 (2001).
48. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198 (1975).
49. Benton AL, Hamsher K deS.Multilingual Aphasia Examination. Iowa City: AJA Associates, 1989.
50. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hha I. J Lipid Res 31: 545-548 (1990).
51. Acer N, Sahin B, Bas O, Ertekin T, Usanmaz M. Comparison of three methods for the estimation of total intracranial volume: stere-ologic, planimetric and anthropometric approaches. Ann Plast Surg 58: 48-53 (2007).
52. Mazziotta J, Toga A, Evans A, Fox P, Lancaster J, Zilles K, et al. A probabilistic atlas and reference system for the human brain: International Consortium for Brain Mapping (ICBM). Phil Trans R Soc Lond B 356: 1293-1322 (2001).
53. Talairach J, Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain: 3-Dimensional Proportional System - an Approach to Cerebral Imaging. New York: Thieme Medical Publishers (1988).
54. Jack CR Jr, Shiung MM, Gunter JL, O'Brien PC, Weigand SD, Knopman DS, et al. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 62: 591-600 (2004).
55. Landen M, Thorsell A, Wallin A, Blennov K. The apolipoprotein E allele epsilon 4 does not correlate with the number of senile plaques or neurofibrillary tangles in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry 61: 352-356 (1996).
56. Maloney B., Lahri DK, The Alzheimer's amyloid -peptyde (Ap) binds a specific DNA Ap-interacting domain (ApID) in the APP, BACE1 and, APOED promoters in a sequence-specific manner: characterizing a new regulatory motif. Gene 48:1-12: (2011).